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Abstract 
Transition metal complexes provide a promising avenue for designing new therapeutic and 
diagnostic agents. In particular, ruthenium(II) polypyridyl complexes are useful for studying 
cellular uptake, due to their easy synthesis and unique photophysical properties. Dyes are frequently 
combined with material substrates to modulate their properties, enhance stability, reduce toxicity, 
and improve delivery. A novel Ru polypyridyl complex linked to a derivative of the natural lipid 
squalene (Ru-BIPPBI-hx-SQ) is described. Using the solvent displacement method, Ru-BIPPBI-hx-
SQ easily self-assembles into nanosized aggregates in aqueous solution, as characterized by 
dynamic light scattering. The nanoassemblies exhibit long-lived and intense luminescence. 
Preliminary biological assessment showed them to be non-toxic; they are efficiently and rapidly 
transported across the cell membrane without requiring its permeabilization. Ru-labeled 
nanoassemblies are likely to be significant cellular-imaging tools, probing cellular events at very 
low concentrations. Moreover co-nanoassembly, with drug-derivatives based on squalenoylation 
technology, including gemcitabine and paclitaxel, has given interesting preliminary results. 
 
∗ Corresponding author. Tel.: +39 0116707082; fax: +39 0112367697. E-mail address: 
franco.dosio@unito.it (F. Dosio). 
 
1. Introduction 
 The nanotechnological approach to pharmacology is of considerable interest, in particular for 
designing drug-delivery tools; it is now leading to the appearance of new treatments with improved 
efficacy (Schroeder et al., 2012). Numerous nanomaterial-based therapeutics are now under 
development. Based on building blocks of different composition (polymeric, lipidic, metal based, 
carbon and biological) nanocompounds have been developed that can carry large amounts of drug, 
releasing it under specific conditions, and with specific targeting moieties. A further advantage of 
using supramolecular structures is that imaging tools for diagnostic therapy can be delivered. The 
concept of chemically linking a terpenoid to a biologically active drug molecule to create a 
bioconjugate that can self aggregate in water, forming nanoassemblies, is a recent development. 
The concept was first applied for a hydrophilic compound, namely gemcitabine (Gem) (Couvreur et 
al., 2006), and later extended to a hydrophobic compound, namely paclitaxel (PTX) (Dosio et al., 
2010). Other relevant anticancer drugs, namely cisplatin, doxorubicin, and siRNA bioconjugates, 
have also been developed (Raouane et al., 2011). Squalenoylation has been employed to embed 
superparamagnetic iron oxide nanoparticles, resulting in a new nanostructured tool for therapeutics 
and diagnosis (Arias et al., 2011). Cellular uptake is critical to evaluate therapeutic or diagnostic 
applications of nanoparticles and small molecules clearly. However, the chemical rules governing 
cellular uptake are not fully understood, and when it can be evaluated the techniques required are 
cumbersome. The most widely used probes in cellular imaging are fluorescent chromophores, 
typically based on polyaromatic organic compounds. Transition metal complexes are increasingly 
applied for biological applications, buttheir uptake properties have not been fully clarified (Boerner 
and Zaleski, 2005; Hart et al., 2006). Luminescent ruthenium complexes have been studied as 
oxygen sensors (Gerritsen et al., 1997) and as DNA intercalators (Zeglis and Barton, 2008). Other 
studies have addressed the use of Ru (II) complexes as anticancer agents (Lentz et al., 2009; Levina 
et al., 2009; Scolaro et al., 2005) and, more recently, as cellimaging probes. For this latter 
application, ruthenium complexes offer several advantages:low background emission, and other 
characteristic photophysical properties including a long-lived excited metal-to-ligand charge 
transfer state, and red-shifted emission. These characteristics combine to make them interesting 
candidates as molecular probes for cellular imaging using fluorescence microscopy. 
Although Ru(II)–polypyridyl complexes have been widely studied, their use in practical 
applications as fluorophores for cellular imaging (Fernandez-Moreira et al., 2010) has remained 
limited. A drawback of some complexes is their inability to efficiently cross cell membranes, and 
various approaches have been attempted to improve cell penetration and specific intracellular 
distribution. A ruthenium complex conjugated to estradiol has been shown to be 
cellpenetrating,probablydue to the lipophilicity ofthe steroidmoiety (Lo et al., 2008). Other 
approaches involve conjugation with cell-penetrating peptides (Neugebauer et al., 2008), with 
biotin (Lo and Lee, 2007), and with Ru–oligonucleotide derivatives (Le Gac et al., 2009). Another 
unexplored field in which Ru(II) complexes might be of interest concerns their use as probes for 
nanoparticles. Initial applications in monitoring the uptake and intracellular fate of silica 
nanoparticles (Besic Gyenge et al., 2011) and of gold nanoparticles (Elmes et al., 2011) have 
recently been reported. With the aim of expanding the squalenoylation platform to include novel 
cell-imaging probes, this study shows that conjugating a bulky complex [Ru(II) bis(2,2 -
bipyridine)-{1-methyl-2- (4-methylpyridin-2-yl)-benzoimidazole}](PF6)2 to squalene leads to the 
construction of stable nanoassemblies in water. Their photophysical properties, cell uptake, and 
distribution are examined. Preliminary evaluations of co-nanoassemblies comprising therapeutic 
and diagnostic tools are also reported.  
 
2. Materials and methods  
2.1. Materials 
 The reagents tert-butoxide, tert-butyl 6-bromohexylcarbamate, ammonium hexafluorophosphate, 
N-hydroxysuccinimide and all solvents were purchased from Sigma Aldrich (Milwaukee, WI), 
Ruthenium(III) chloride hydrate was purchased from Alfa Aesar (Karlsruhe, Germany) and used as 
received. 2-(4-Methylpyridin- 2-yl)-1H-benzoimidazole (Barni and Savarino, 1977), Dichlorobis 
(dipyridyl)Ruthenium (II) dihydrate [cis-[Ru(bpy)2Cl2]·2H2O] (Sullivan et al., 1978) and N-
hydroxysuccinimido diphenyl phosphate (SDPP) (Ogura et al., 1980) were prepared by known 
methods. 1,1 ,2-Trisnorsqualenoic acid was prepared as described in Ceruti et al. (1987) starting 
from squalene, via the intermediates squalene monobromohydrine and squalene 2,3-epoxide. The 
squalenoyl derivatives of Gem and PTX were prepared as described elsewhere (Couvreur et al., 
2006; Dosio et al., 2010). In all studies involving fluorescence and in all cell tests, the compound 
[Ru(II) bis(2,2 -bipyridine){1-methyl-2-(4- methylpyridin-2-yl)-benzoimidazole}] (PF6)2 (Ru-
BPPBI), synthesized as described in Gobetto et al.(2006), was used for comparison. This compound 
was dissolved in dimethylsulfoxide before dilution in test solutions. The 1H NMR spectra were 
recorded using a NMR Bruker Avance 400 spectrometer (Bruker AXS Inc., Madison, WI). 
Spectroscopic signals were referenced to the residual solvent peak. The following abbreviations are 
used: s, singlet; d, doublet; t, triplet; m, multiplet. Elemental analyses were carried out by Redox 
Snc (Monza, Italy). Quasi-elastic light scattering (QELS) and zeta potential were measured using a 
90 Plus Particle Size Analyzer (Brookhaven Instruments, Co., Holtsville, NY) photometer. UV-vis 
spectra were recorded using a Beckman 730 spectrophotometer with a temperature controller. Mass 
spectra were recorded with a Finnigan Mat TSQ700 and Waters Micromass ZQ (ESCI and APCI 
sources) (Waters Corp. Milford, MA). Photoemission spectra were acquired with a Horiba Jobin 
Yvon Fluorolog3 TCSPC spectrofluorimeter (Horiba Ltd., Minami-KuKyoto, Japan). 
 2.2. Synthesis  
2.2.1. tert-Butyl 6-(2-(4-methylpyridin-2-yl)-1H-benzoimidazol- 1-yl)-hexylcarbamate Freshly 
sublimated potassium tert-butoxide (0.160 g, 1.40 mmol) was added to a solution of 2-(4-
methylpyridin- 2-yl)-1H-benzoimidazole (0.250 g, 1.20 mmol) in anhydrous 
dimethylformamide/anhydrous diethyl ether (4 mL/8 mL), at room temperature in argon. After 
stirring for 15 min, a solution of tert-butyl 6-bromohexylcarbamate (1.14 g, 4.06 mmol) in 
dimethylformamide (2 mL) was added dropwise. After 8 h of heating at 60 ◦C, the mixture was 
cooled to room temperature, poured into water (10 mL) and extracted with chloroform (4 × 10 mL). 
The organic layers were dried with anhydrous sodium sulfate, evaporated under vacuum, and 
purified chromatographically over silica gel using diethyl ether as eluent. A yellowish solid was 
obtained with a yield of 75% (0.368 g). 1H NMR (400 MHz, [D4]-methanol): ı = 8.60 (d, 1H, 3J = 
5.0 Hz), 8.03 (s, 1H), 7.72 (d, 1H, 3J = 7.9 Hz), 7.61 (d, 1H, 3J = 7.9 Hz), 7.39–7.30 (m, 3H), 4.77 
(t, 2H, 3J = 7.3 Hz), 2.95 (t, 2H, 3J = 6.8 Hz), 2.50 (s, 3H), 1.83 (m, 2H, 3J = 6.8/7.3), 1.42 (s, 9H), 
1.37 (m, 2H), 1.28 (m, 4H) ppm. m/z C24N4O2H32(ESI): 409 [M+H]+, 431 [M+Na]+.  
2.2.2. [Ru(II) bis(2,2 -bipyridine) {6-[2-(4-methyl-pyridin-2-yl)- 1H-benzoimidazol-1-yl]-
hexylamine}](PF6)2 [Ru(bpy)2Cl2]·2H2O (0.300 g, 0.576 mmol) and tert-butyl 6-(2- (4-
methylpyridin-2-yl)-1H-benzoimidazol-1-yl)-hexylcarbamate (0.280 g, 0.685 mmol) were 
dissolved in ethylene glycol (50 mL). The mixture was degassed with argon for 15 min and then 
refluxed for 6 h. After cooling to room temperature, water (20 mL) and an aqueous solution of 
NH4PF6 (1.0 g/10 mL) were added. The precipitate was then collected, washed with water (10 mL) 
and dried with diethyl ether. 0.420 g (0.415 mmol) of [Ru(II) bis(2,2-bipyridine) {6-[2-(4-methyl-
pyridin-2-yl)-1Hbenzoimidazol-1-yl]-hexylamine}](PF6)2 were obtained (yield 72%). 1H NMR 
(400 MHz, [D3]-acetonitrile): ı = 8.50 (m, 3H), 8.41 (d, 1H, 3J = 8.0 Hz), 8.19 (s, 1H), 8.10 (m, 
1H), 8.08–8.03 (m, 2H), 7.96 (t, 1H, 3J = 7.9), 7.91 (d, 1H, 3J = 5.5), 7.80 (d, 1H, 3J = 5.4), 7.74 
(m, 3H), 7.62 (d, 1H, 3J = 5.7), 7.46–7.30 (m, 5H), 7.25 (d, 1H, 3J = 5.2), 7.05 (t, 1 H, 3J = 8.0), 
5.81 (d, 1H, 3J = 8.4), 4.80 (m, 2H), 2.58 (s, 3H), 2.10 (m, 1H), 1.99 (m, 2H), 1.40 (m, 6H) ppm. 
 2.2.3. Squalene- N-hydroxysuccinimide Ester   1,1 ,2-Trisnorsqualenoyl-N-hydroxysuccinimide 
ester (SQNHS) was synthesized using the SDPP reagent. Briefly, SDPP (1.5 equiv.) dissolved in 
anhydrous dichloromethane (10 mL) with triethylamine (4 equiv.) was added to a solution of 1,1 ,2- 
trisnorsqualenoic acid (300 mg, 0.749 mmol). The mixture was stirred for 3 h at room temperature 
and then concentrated under vacuum. The crude reaction mixture was dissolved in dichloromethane 
and extracted with brine, and further dried with magnesium sulfate. The reaction product did not 
require any further purification (yield 85%). ESI-MS calculated for SQ-NHS Found: 498.72 
(M+H+). 
 2.2.4. Squalenoyl- [Ru(II) bis(2,2 -bipyridine) {6-[2-(4-methylpyridin-2-yl)-1H-benzoimidazol-1-
yl]-hexylamine}](PF6)2 (Ru-BIPPBI-hx-SQ) [Ru(II) bis(2,2 -bipyridine) {6-[2-(4-methyl-pyridin-
2-yl)-1Hbenzoimidazol-1-yl]-hexylamine}](PF6)2 (60 mg, 0.06 mmol) was dissolved in anhydrous 
dichloromethane (6 mL). An equivalent molar amount of SQ-NHS (30 mg) and triethylamine (10 
µL, d = 0.76) were added under stirring and the reaction was allowed to continue for 4 h at 20 ◦C. 
After solvent removal, the crude mixture was purified by SiO2 gel chromatography with linear 
gradients, using a dichloromethane/ethanol mixture as eluent, 98:2–90:10. Rf 
(dichloromethane/ethanol 9:1) = 0.4. A dark red oil resulted, with a yield of 75% (83 mg). 
C66H82F6N8OPRu m/z 1250.01 (M–PF6+H), peaks representative of Ru pattern. 1H NMR (400 
MHz, CDCl3): ı = 8.52 (m, 3H), 8.41 (s, 1H, 3J = 8.0 Hz), 8.09–8.03 (m, 2H), 7.97 (t, 1H, 3J = 
7.9), 7.90 (d, 1H, 3J = 5.4), 7.80 (d, 1H, 3J = 5.4), 7.74 (m, 3H), 7.61 (d, 1H, 3J = 5.5), 7.46–7.30 
(m, 5H), 7.25 (d, 1H, 3J = 5.2), 7.05 (t, 1H, 3J = 7.8), 5.20 (m, 5H), 5.06 (s, 2H), 4.80 (m, 2H), 3.12 
(t, 2H, 3J = 6.2), 2.43 (m, 5H), 2.31 (m, 4H), 2.00–1.89 (m, 18H), 1.69 (m, 2H), 1.61 (m, 20H), 
1.38 (m, 6H) ppm. 
 2.2.5. Preparation of nanoassemblies  
Nanoassemblies (NAs) were prepared as follows: the Ru-BPPBIhx-SQ conjugate was dissolved in 
acetone (4–8 mg/mL), after which the organic solution was added dropwise under rapid stirring into 
MilliQ grade water. Finally, the organic solvent was completely evaporated using Rotavapor®, 
leaving an aqueous suspension of NAs. In a typical nanoassembled preparation, the final 
concentration of Ru-BPPBI-hx-SQ was 2 mg/mL. Co-nanoprecipitation was achieved by dissolving 
precise amounts of squalenoyl derivatives of paclitaxel (PTX-SQ) or gemcitabine (Gem-SQ) (1 mg) 
with different molar proportions of Ru-BPPBI-hx-SQ (10%, 5%, 1%) in acetone, and following the 
above procedure. 
 2.3. Characterization  
2.3.1. Size and zeta potential measurements  
The average diameter and polydispersity index of the nanoassemblies were determined using quasi-
elastic light scattering (QELS) at a fixed angle of 90 ◦C and at a temperature of 25 ◦C. The NA 
dispersions were diluted (10% or 20%) with MilliQ water before analysis. Each value reported is 
the average of ten measurements. To determine the electrophoretic mobility, the NA samples were 
diluted with 0.1 mM KCl and placed in the electrophoretic cell, where an electric field of 
15.24V/cm was established. Each sample was analyzed in triplicate. Zeta potential values were 
calculated using the Smolochowski equation. The stability of NAs was assessed by repeating size 
measurements of Ru-BPPBI-hx-SQ or of co-nanoassemblies up to 15 days after storage at 5 ◦C in 
the dark. 
 2.3.2. Photophysical characterization 
 Electronic absorption and photoemission spectra were recorded at room temperature in acetonitrile 
solution (Ru-BPPBI-hxSQ, [Ru(II) bis(2,2 -bipyridine) {6-[2-(4-methyl-pyridin-2-yl)-
1Hbenzoimidazol-1-yl]-hexylamine}](PF6)2, and Ru-BPPBI) or in aqueous solution (Ru-BPPBI-
hx-SQ nanoassembly). Photoemission spectra were recorded in both degassed and air-saturated 
solutions. Photoemission spectra were acquired with a Horiba Jobin Yvon Fluorolog3 TCSPC 
spectrofluorimeter equipped with a 450W Xenon lamp and a Hamamatsu R928 photomultiplier. 
The spectral response was corrected for the spectral sensitivity of the photomultiplier. 
Luminescence quantum yields (ϕ) were determined using [Ru(bpy)3]Cl2 as standard (ϕ = 0.062) 
(Juris et al., 1988). The refractive index was corrected to account for the specific solvent used 
Luminescence lifetimes were determined by time-correlated single-photon counting (TCSPC). 
Excitation was with nanosecond pulses of 455 nm light (repetition rate 100 kHz) generated by a 
NanoLED pulsed diode. Emission data were collected using a spectral bandwidth of 5 nm at 90 ◦C 
to a TBX-4 detector. Data were collected into 1024 channels, to 10,000 counts in the peak channel. 
Emission decay data were analyzed using the software package DAS6 (TCSPC Decay Analysis 
Software). 
 2.3.3. Cell tests 
 Cell cultures: human breast-cancer cells (MCF-7, ATCC HTB-22) and human colorectal-
adenocarcinoma cells (HT-29, ATCC HTB-38) were cultured in DMEM and RPMI, respectively, 
both supplemented with 10% foetal bovine serum (Invitrogen), and 1% antibiotics (containing 
penicillin and streptomycin, Invitrogen). The medium was changed every other day, and the culture 
was incubated at 37 ◦C in a humidified atmosphere containing 5% CO2. The liquid overlay 
technique was used to generate multicellular spheroids (Wartenberg and Acker, 1995). Briefly, cell 
monolayers of HT-29 were trypsinized and seeded on agarose-coated 10 cm Petri dishes at 1 × 105 
cells/mL, in an incubator (37 ◦C, 5% CO2). A proportion of the cell-culture medium was changed 
daily. After 4 days of liquid overlay, the spheroids were stable in form; they reached the desired 
diameter of 70–100 m two days later. Selected multicellular spheroids were transferred to 35-mm 
Petri dishes in 2 mL of medium, and exposed to Ru-BPPBI-hx-SQ NA or to Ru-BPPBI (final 
concentration 50 µM) for 2 h, then washed three times in RPMI; fluorescence intensity was then 
measured using a confocal laser scanning microscopy technique, as described below.  
2.3.4. Inductively coupled plasma mass spectrometric (ICPMS) detection of Ru 
 The MCF-7 cell line was grown to ∼30% confluence in 75 cm2 flasks, and incubated with 50 µM 
of either Ru-BPPBI or Ru-BPPBIhx-SQ for 1 h at 37 ◦C in serum-free medium. Cells were rinsed 
with RPMI, detached with trypsin, and counted. Aliquots of 3–4 million cells were isolated by 
centrifugation and digested with 1 mL of concentrated nitric acid (65%) for 1.5 h at 60 ◦C. The 
solution was diluted with 10 mL double-distilled water. The 102Ru content was measured using a 
Thermo Electron Corporation ELEMENT2 Inductively Coupled Plasma-Sector Field Mass 
Spectrometer (Thermo Fisher Sci., Waltham, MA, USA) by comparison with a standard curve of 
[Ru(bpy)3]Cl2 . 6 H2O (range 1–70 ppb). Data are reported as means plus standard deviation (n = 
3). 
 2.3.5. Cytotoxicity assay 
 Cytotoxicity was assayed on MCF7 and HT-29 carcinoma cell lines, incubating the cells with 
different concentrations of NAs or Ru compounds for 72 h (37 ◦C, 5% CO2). The supernatant was 
removed, and the cells were washed and incubated for 16 h with 200 mL of medium containing 31 
mCi of L-[4,5- 3H]leucine (58 Ci/mmole) (Amersham). The cells were removed from the plates 
using Nonidet P-40 (1‰) and the incorporated radioactivity measured in a LS-5000TD beta-counter 
(Beckman). Results are expressed as percentage L-[4,5-3H]leucine incorporation versus controls; 
background values were subtracted. The experiment was repeated three times, in triplicate, for each 
concentration of the compounds. 
 2.3.6. Confocal laser scanning microscope studies 
 HT-29 and MCF-7 cell lines (about 0.3 × 106 cells) were seeded onto sterile glass two-well 
chamber slides 4.2 cm2 Lab-TekTM (Nunc Thermo Fisher Sci.) and cultured overnight (to about 
70% confluence) prior to the experiments. Cells were washed twice with fetal-bovine-serum-free 
RPMI, and incubated for 2 h at 37 ◦C, 5% CO2, with either Ru-BPPBI-hx-SQ NA or Ru-BPPBI, 
diluted to 50 µM. After 2 h, cells were incubated with 200 µL of 4 ,6- diamidino-2-phenylindole 
(DAPI) (1 µg/mL in a free-serum RPMI; ex = 365 nm–em = 454 nm) for 30 min at 37 ◦C. Cells 
were then washed with PBS (2 × 2 mL) and fixed at room temperature with 50:50 (v/v) 
acetone:methanol solution (1 mL, maintained at 5 ◦C for 5 min) then washed with PBS (2 × 2 mL) 
and dried thoroughly in air. One drop of glycerol was added, and covered with a glass slide. A 
Leica DM3000 microscope was used (Leica Microsystems, Mannheim, Germany) with a Leica 
Confocal System equipped with a 3 channel multiband scanner Leica TCS SP2. Confocal 
fluorescence images were recorded using a 40X Apochromat water-immersion objective lens, with 
a numerical aperture of 1.4. Ru compounds were imaged using the Ar laser bands at 458, 476 and 
488 nm for excitation, and an emission window at 600–700 nm. A 405 nm diode was used to excite 
DAPI, whose fluorescence was recorded at 450–500 nm. Scanning resolution was set to 1024 × 
1024 pixels. Multifocal images of spheroids were acquired with 3 µm intervals between adjacent 
optical sections, for a total depth of 100 µm. To determine fluorescence related to Ru compounds, 
20 different cell areas (60 µm2) were selected and analyzed for their average fluorescence intensity 
in the 600–700 nm range, together with a background area (1500 µm2). Photobleaching was tested 
on HT-29 cells, selecting an area of 800 µm2 and irradiating with argon ion laser, at 458 nm, 476 
nm or 488 nm, with 5 s impulses for 20 min. A similar but non-irradiated area was used as control. 
The fluorescence emitted by the cells was recorded as image sequences (1024 × 1024 pixels, 96 dpi 
and 8 bit colour depth) and fluorescence intensity analysis was performed with the Leica LCS 
software. 
 3. Results and discussion  
In previous work, the squalenoylation platform developed by our group was employed to design 
self-assembling nanomedicines derived from hydrophilic therapeutic agents, namely Gem, 2 ,3 - 
dideoxycytidine, and 2 ,3 -dideoxyinosine (Bekkara-Aounallah et al., 2008; Couvreur et al., 2006). 
The technology was then extended to include a highly lipophilic drug, PTX (Dosio et al., 2010); it 
has now been applied to increase the range of applications of in vitro diagnostic tools, resulting in 
lipophilic prodrugs that produce stable nanosuspensions.  
3.1. Synthesis  
In order to obtain a compound that is stable in vitro, the luminophor was linked to the squalenoyl 
moiety via an amide group (Scheme 1). Firstly, an analogue of the complex Ru-BPPBI (Gobetto et 
al., 2006) (Scheme 1) bearing a linker suitable for conjugation was synthesized. This was achieved 
by exploiting the reactivity of the ligand’s precursor, namely 2-(4-methylpyridin-2- yl)-1H-
benzoimidazole, which was regioselectively modified at the NH group by reaction with tert-butyl 6-
bromohexylcarbamate. The resulting ligand, tert-butyl 6-(2-(4-methylpyridin-2-yl)- 1H-
benzoimidazol-1-yl)-hexylcarbamate, was then reacted with cis-[Ru(bpy)2Cl2] to provide the 
complex [Ru(II) bis(2,2 - bipyridine) {6-[2-(4-methyl-pyridin-2-yl)-1H-benzoimidazol- 1-yl]-
hexylamine}](PF6)2 (Scheme 1A). The new luminophor contains a six-carbon aliphatic chain with a 
terminal reactive amino group, and was conjugated to the squalenoyl moiety by reaction with an 
equimolar amount of SQ-NHS in the presence of triethylamine (Scheme 1B), leading to Ru-BPPBI-
hx-SQ in good yield. The advantage of using SQ-NHS, instead of employing an in situ reaction 
with carbodiimides, lies in the increased yield and reduction of by-products. 
 3.2. Nanoassemblies: preparation and characterization 
 The squalenoyl-Ru complex was formulated as nanoassemblies in water, using a simple 
nanoprecipitation technique without surfactants. Nanoprecipitation of Ru-BPPBI-hx-SQ yielded 
assemblies of about 300 nm in diameter physically stable, measured via particle size, at 
concentrations in the range 2–4 mg/mL. In comparison, Ru-BPPBI is poorly soluble in water. The 
co-nanoassembly of squalenoyl derivatives was achieved by first dissolving both components in 
acetone and then pouring them both into a rapidly-mixed water solution. Different molar ratios were 
tested, evaluating the size of the resulting NAs and their stability over time. It was found (Table 1) 
that, with PTX, which is more hydrophobic and has a more rigid structure, 1:20 is the best Ru-
SQ:PTX-SQ ratio; on increasing this ratio, micrometer precipitation rapidly occurred. Conversely, 
with Gem-SQ, more hydrophilic and more stable, the ratio could be doubled. Fig. 1 shows the 
opaque and colored appearance of the NAs. For comparison, when equal amounts of two preformed 
NA solutions were combined, size and charge of PTX-SQ and of Gem-SQ remained substantially 
unchanged (data not shown). When the quantity of Ru-BPPBI-hx-SQ added to the other prodrug 
NAs was increased, there first occurred a reduction of mean NA size, and then, at a ratio of 1:1, 
rapid and complete precipitation. All NAs had negative zeta potential, although Ru-BPPBI-hx-SQ 
presented the highest value (due to a mixing effect of the complex positive charge, the role of bulky 
counter-ions, and the solvent) (Cheng, 2006). The physical stability of the NAs was assessed by 
measuring the size after 15 days’ storage at 5 ◦C. The samples containing Ru-BPPBI-hx-SQ showed 
a significant size increase, unlike pure PTX and Gem conjugates. Of the co-nanoassemblies, Gem-
SQ appeared to improve NA stability. 
 3.3. Photophysical properties of complexes 
 Electronic absorption spectra of Ru-BPPBI-hx-SQ and [Ru(II) bis(2,2 -bipyridine) {6-[2-(4-
methyl-pyridin-2-yl)-1Hbenzoimidazol-1-yl]-hexylamine}](PF6)2, recorded at room temperature in 
acetonitrile solution, were virtually identical to the spectrum of the precursor Ru-BPPBI (Fig. 2). 
The absorption spectra of the three complexes are characterized by an absorption band centred at 
460 nm (ε = 12.2 × 103 L mol−1 cm−1), which is assigned to a metal-to-ligand charge transfer 
(MLCT) transition. The modification is relatively distant from the metal center, and has little 
influence on electronic properties. As occurs with the parent complex (Ru-BPPBI), the two 
derivatives show an intense emission centred at 634 nm, with a quantum yield of 0.02. The 
luminescence lies in the red part of the spectrum, distant from any possible autofluorescence of 
biological material. The luminescence lifetimes of the three complexes are virtually identical: 520 
ns for Ru-BPPBI-hx-SQ, and 510 ns for the other two complexes (degassed acetonitrile solution). 
This long-lived luminescence may be appropriate to explore some of the longer-lasting biodynamic 
processes (e.g. membrane diffusion, protein rotation, protein folding). Furthermore, the 
luminescence lifetime of the three complexes is oxygen-sensitive: in air-saturated acetonitrile 
solution it decreased to 130 ns. When excited at 460 nm, the Ru-BPPBI-hx-SQ Na showed an 
unstructured emission centered at 630 nm, very similar to the emission of free Ru in acetonitrile 
solution. Due to the high concentration of luminophor in the NA solution, it was not possible to 
acquire the absorption spectrum. However, the excitation spectrum recorded at 630 nm is almost 
identical to the absorption spectrum of free Ru-BPPBI-hx-SQ (Fig. 2). The main difference 
between NA and free Ru-BPPBI-hx-SQ lies in their luminescence lifetimes. The emission of NA in 
degassed aqueous solution has a lifetime of 310 ns, shorter than the lifetime of free Ru-BPPBI-
hxSQ (510 ns in degassed acetonitrile solution). Conversely, the NA solution is less sensitive to the 
concentration of dissolved oxygen, and the lifetime decreases only slightly in air-saturated aqueous 
solution (280 ns).  
3.4. In vitro activity: cellular uptake 
 To investigate cellular uptake and the cytotoxicity of Ru-BPPBIhx-SQ, two well-known human 
cancer cell lines were used, HT-29 colorectal and MCF-7 breast lines, frequently employed to 
screen drug compounds and, in particular used to test several Ru complexes (Oehninger et al., 2011; 
Reddy et al., 2012; Schatzschneider et al., 2008). The cellular localization of the complexes was 
studied by CLSM, and Figs. 3 and 4 show characteristic cellular staining patterns. DAPI, a 
fluorescent stain for DNA, was used to stain the cell nucleus clearly. In a typical protocol, Ru-
BPPBI-hx-SQ NA and the parent compound were diluted to a final concentration of 50 µM and 
incubated for 2 h. The CLSM experimental conditions were set to 458–488 nm for the range for 
excitation, corresponding to MLCT transition, while the absorbance of the metal complex and the 
emission images were recorded at 600–620 nm. No DAPI interference with Ru complex 
luminescence occurred (Abs max 358 nm, emission maximum 461 nm). Very little luminescence 
was observed inside HT-29 cells treated with Ru-BPPBI (Fig. 3, top) indicating that the dye cannot 
easily penetrate the cell membrane and enter the cell, even after 2 h incubation. This confirmed data 
reported for [Ru(bpy)2-(4- carboxyphenyl)imidazo[4,5-f] (phen)]2+ (Neugebauer et al., 2008) and 
for [Ru(bpy)2dppz]2+ and [Ru(phen)2dppz]2+ (Puckett and Barton, 2007) (phen = 1,l0-
phenanthroline; dppz = dipyrido[3,2- a:2 ,3 -c]phenazine). In contrast (Fig. 3, bottom), Ru-BPPBI-
hx-SQ is passively transported through the cell membrane and accumulates inside the cell: the 
luminescence intensity of the cell population increased by 400%. Interestingly, the cell nucleus was 
equally stained, unlike what has been reported in other studies (Puckett and Barton, 2007) for a 
highly hydrophobic Ru(DIP)2dppz 2+ (DIP = 4,7-diphenyl-1,10-phenanthroline) derivative. Fig. 4 
shows the luminescence emitted by MCF-7 when stained with Ru-BPPBIhx-SQ: ruthenium 
luminescence is clearly visible throughout the cytoplasm. Inductively-coupled plasma mass 
spectrometry (ICP-MS) measurements were performed to quantify the amount of Ru taken up by 
cells. MCF-7 cells were treated with 50 M of Ru-BPPBI or Ru-BPPBI-hx-SQ in serum-free 
medium. ICP-MS measures gave 270 ± 12 amol of Ru per cellfor Ru-BPPBI-hx-SQ and 13± 6 amol 
per cell for the non-squalenoyl complex. These results confirmed the distribution of the lipophilic 
complex inside the cell, and indicated Fthat the concentration of the squalenoyl complex (160 M) 
within the cell was substantial, well above the exposure concentration. To improve our knowledge 
of cell uptake and diffusion of squalenoyl derivatives, experiments were also run on 
threedimensional cell cultures. This method has the advantage of maintaining some of the in vivo 
cellular architecture and interactions of cancer cells. Furthermore, the spheroids are a model of 
micrometastatic, prevascularized tumors (Helmlinger et al., 1997; Jacks and Weinberg, 2002). Fig. 
5 is a representative CLSM equatorial section image of an HT-29 spheroid incubated for 2 h with 
Ru-BPPBI-hx-SQ. The luminescence is widely diffused and only the inner core appears dark. These 
results clearly demonstrate that the high lipophilicity of the compound allows it to bind to the 
spheroid rim, and provides rapid diffusion among intracellular spaces, leading to well-distributed 
intratumoral penetration. 
 3.4.1. Cytotoxicity 
 In order to evaluate the role of Ru-complexes on cell viability, HT-29 and MCF-7 cell lines were 
incubated extensively (72 h at 37 ◦C, 5% CO2 in media with foetal calf serum) with high 
concentrations (up to 2 mM) of compound. Inhibition of protein synthesis was checked by 
measuring the incorporation of tritiated leucine. Ru-BPPBI presented an IC50 of 270 and 420 µM, 
on MCF7 and HT- 29 cells respectively. The squalenoyl derivative appeared as toxic as the parent 
compound against HT-29 cells (IC50 380 µM) and slightly more toxic against MCF-7 (110 µM). It 
is important for a cell-imaging probe to have very low cytotoxicity, and squalenoylation, applied to 
potent anticancer agents, has been found to modulate their cytoxicity, reducing systemic side effects 
(Dosio et al., 2010; Raouane et al., 2011; Réjiba et al., 2011). In the present case, although a 
significant increase in lipophilicity was observed, with a related increase in cellular diffusion, the 
Ru complex did not cause significant inhibition of protein synthesis. It is important to note that, in 
the case of other Ru(II) compounds, for example [Ru (bpy)2(N-N)]2+ containing lipophilic bidentate 
aromatic ligands, the toxicity rose to 3 µM (against MCF-7) and to 6 µM (against HT-29) when 
tested with the same incubation times used Fig. 6. Trend of Ru-BPPBI-hx-SQ luminescence 
emission after 20 min of continuous irradiation of treated HT-29 cells used here (Schatzschneider et 
al., 2008). This toxicity level of the ruthenium(II) polypyridyl complexes is similar to that of 
cisplatin, a potent anticancer agent.  
3.4.2. CLSM to monitor photobleaching of the Ru complex 
 A drawback of conventional organic chromophores for laser scanning microscopy is their 
propensity to photobleach, which limits their use over extended periods (Diaspro et al., 2006). 
Under the imaging conditions given above, selected area containing a group of HT-29 cells, 
previously incubated with Ru-BPPBI-hx-SQ, were submitted to 20 min of continuous pulsed 
irradiation. The diffused compound retained more than 60% of its initial luminescence intensity 
(Fig. 6). This photostability, combined with uniform diffusion inside cells, may make the complex 
useful for studying the dynamics of cellular processes. 
 4. Conclusions  
This study reports the production of a Ru complex capable of self-assembling into nanoparticles in 
aqueous media. Even for the bulky aromatic Ru complex (volume of 4005.9 Å3) (Gobetto et al., 
2006), the bioconjugate obtained by linking the squalenoyl moiety provided a supramolecular 
assembly, as occurs with other planar metal complexes such as cis-platin (Arias et al., 2011). The 
lipophilicity induced by the squalene chain appeared to be flexible, and to improve cell uptake and 
diffusion, including in multicellular spheroids. It also packed, to allow supramolecular assembly as 
occurs with other drug squalenoyl derivatives. Unlike Gem-SQ, which is metabolized by the 
endothelial reticulum and does not penetrate the cell nucleus (Bildstein et al., 2010), Ru-BPPBI-
hxSQ concentrates inside the cell, diffusing into the cytoplasm and intracellular organs. It is also 
able to diffuse throughout a more organized cell system, in the form of multicellular spheroid. 
Further, unlike other bidentate aromatic derivatives (Schatzschneider et al., 2008), Ru-BPPBI-hx-
SQ does not exercise significant toxicity. Preliminary studies of the co-nanoassembly show that this 
Ru-complex may be distributed inside drug-SQ prodrugs, and appears to stabilize the Gem-SQ NA 
to a greater extent than does PTX-SQ. Further studies will be required to fully determine the 
structure of co-nanoassemblies. Moreover, other in vitro studies are needed to evaluate the role of 
the individual components of co-nanoassemblies in the release, uptake and diffusion into cells. 
However, the squalenoylation platform has demonstrated its relevance, not only in the drugability 
of therapeutic agents, but also for the development of novel cell diagnostic tools. 
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